Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-819 in BCG-unresponsive NMIBC
NCT03719300Phase 2Terminated
- Sponsor
- Anchiano Therapeutics Ltd.
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inodiftagene vixteplasmid in non-muscle-invasive bladder cancer (NMIBC), sponsored by Anchiano Therapeutics Ltd. Primary endpoint: Complete Response Rate at 12 weeks. Started Mar 2019; status: terminated.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03719300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719300.